These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28429561)

  • 1. cfDNA screening performance: accounting for and reducing test failures.
    Cuckle H
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):689-692. PubMed ID: 28429561
    [No Abstract]   [Full Text] [Related]  

  • 2. ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice.
    Salomon LJ; Alfirevic Z; Audibert F; Kagan KO; Paladini D; Yeo G; Raine-Fenning N;
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):815-816. PubMed ID: 28573775
    [No Abstract]   [Full Text] [Related]  

  • 3. Positive view and increased likely uptake of follow-up testing with analysis of cell-free fetal DNA as alternative to invasive testing among Danish pregnant women.
    Miltoft CB; Rode L; Tabor A
    Acta Obstet Gynecol Scand; 2018 May; 97(5):577-586. PubMed ID: 29350746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating thyroid markers in Down syndrome screening protocols.
    Dhaifalah I; Salek T; Langova D; Cuckle H
    Prenat Diagn; 2017 May; 37(5):510-514. PubMed ID: 28374559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concerns following rapid implementation of first-line screening for aneuploidy by cell-free DNA analysis in the Belgian healthcare system.
    Abousleiman C; Lismonde A; Jani JC
    Ultrasound Obstet Gynecol; 2019 Jun; 53(6):847-848. PubMed ID: 30937993
    [No Abstract]   [Full Text] [Related]  

  • 6. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory.
    Petersen AK; Cheung SW; Smith JL; Bi W; Ward PA; Peacock S; Braxton A; Van Den Veyver IB; Breman AM
    Am J Obstet Gynecol; 2017 Dec; 217(6):691.e1-691.e6. PubMed ID: 29032050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A unified approach to risk assessment for fetal aneuploidies.
    Wright D; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):48-54. PubMed ID: 25315809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obstetrical provider knowledge and attitudes towards cell-free DNA screening: results of a cross-sectional national survey.
    Chan WV; Johnson JA; Wilson RD; Metcalfe A
    BMC Pregnancy Childbirth; 2018 Jan; 18(1):40. PubMed ID: 29361931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA.
    Johnson J; Pastuck M; Metcalfe A; Connors G; Krause R; Wilson D; Cuckle H
    Prenat Diagn; 2013 Nov; 33(11):1044-9. PubMed ID: 23836291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological explanations for discordant noninvasive prenatal test results: Preliminary data and lessons learned.
    Wilkins-Haug L; Zhang C; Cerveira E; Ryan M; Mil-Homens A; Zhu Q; Reddi H; Lee C; Bianchi DW
    Prenat Diagn; 2018 May; 38(6):445-458. PubMed ID: 29633279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal screening costs at a large military treatment facility.
    Shiv E; Sale TJ; Simsiman A; Leininger WM; Lutgendorf MA
    J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1584-1587. PubMed ID: 27431854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis.
    Cuckle H; Benn P; Pergament E
    Prenat Diagn; 2013 Jul; 33(7):636-42. PubMed ID: 23674341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free DNA analysis for noninvasive examination of trisomy.
    Norton ME; Jacobsson B; Swamy GK; Laurent LC; Ranzini AC; Brar H; Tomlinson MW; Pereira L; Spitz JL; Hollemon D; Cuckle H; Musci TJ; Wapner RJ
    N Engl J Med; 2015 Apr; 372(17):1589-97. PubMed ID: 25830321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Free DNA Screening: Complexities and Challenges of Clinical Implementation.
    Grace MR; Hardisty E; Dotters-Katz SK; Vora NL; Kuller JA
    Obstet Gynecol Surv; 2016 Aug; 71(8):477-87. PubMed ID: 27526871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debates on fetal fraction measurement and DNA-based noninvasive prenatal screening: time for standardisation?
    Wataganara T; Bui TH; Choy KW; Leung TY
    BJOG; 2016 Sep; 123 Suppl 3():31-5. PubMed ID: 27627594
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures.
    Palomaki GE; Eklund EE; Neveux LM; Lambert Messerlian GM
    Prenat Diagn; 2015 Aug; 35(8):789-96. PubMed ID: 25967109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-invasive genetic tests for fetal trisomy 21 detection: current considerations].
    Benachi A; Costa JM
    J Gynecol Obstet Biol Reprod (Paris); 2014 Mar; 43(3):195-7. PubMed ID: 24529921
    [No Abstract]   [Full Text] [Related]  

  • 18. [Non-invasive prenatal testing is a breakthrough in prenatal screening].
    Hornstrup LS; Ambye L; Sørensen S; Jørgensen FS
    Ugeskr Laeger; 2015 Jul; 177(28):. PubMed ID: 26239855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What will be the role of first-trimester ultrasound if cell-free DNA screening for aneuploidy becomes routine?
    Sonek JD; Cuckle HS
    Ultrasound Obstet Gynecol; 2014 Dec; 44(6):621-30. PubMed ID: 25449114
    [No Abstract]   [Full Text] [Related]  

  • 20. Cell Free DNA and Procalcitonin as Early Markers of Complications in ICU Patients with Multiple Trauma and Major Surgery.
    Ahmed AI; Soliman RA; Samir S
    Clin Lab; 2016 Dec; 62(12):2395-2404. PubMed ID: 28164563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.